Pharma sponsors · CROs

Available

Enrollment slots

Low

Screen failure rate — credentialed network

Registered studies — FDAAA 801

Field-by-field

Criterion classification

The 104-gene panel covers BRCA1/2, ATM, CDK12, PALB2, and full HRR pathway genes for mCRPC. FGFR3 activating mutations for urothelial carcinoma. VHL, PBRM1, BAP1, and SETD2 for clear cell RCC. Each variant class maps to a recruiting trial category in the VerifiedEnroll network.

TrialChecker classifies each patient-trial pair criterion by criterion against published eligibility criteria — mutation status, ECOG performance, prior therapy lines, organ function thresholds. Any structured genomic result is accepted: 104-gene ctDNA panel, Guardant360, Foundation Medicine, or tissue CGP. Candidates arrive with field-by-field eligibility documentation. No data sharing required from the sponsor.

Sponsor inquiry

Mechanism

Genomic result to enrolled candidate — four steps.

Criterion-by-criterion candidate identification

TrialChecker evaluates each patient-trial pair criterion by criterion against published eligibility criteria. Mutation status, ECOG performance, prior therapy lines, organ function thresholds — each criterion checked against patient-specific values. Candidates delivered with field-by-field eligibility documentation per published protocol criteria.

Panel-agnostic genomic input

104-gene ctDNA panel, Guardant360, Tempus xF+, Foundation Medicine, or tissue CGP. Any structured genomic result is accepted. SNVs, indels, copy number alterations, MSI. 0.1% VAF sensitivity on the Atumnus panel. Processed at partner lab under existing CLIA certification. Gene-to-therapy matrix maps output to registered trial eligibility criteria.

Registered studies — ClinicalTrials.gov FDAAA 801

Atumnus LLC. IRB-approved protocols. Available enrollment slots. Companion diagnostic testing channel operates outside Medicare billing. Flat-fee companion diagnostic — per sponsor agreement — sponsor to lab, direct. Enrollment open. No data sharing required from sponsor.

Independent physician sub-investigator network

Credentialed urologists, oncologists, and hematology/oncology physicians. NPI-direct credentialing in 48 hours. No hospital affiliation required. Sub-investigator agreements on Atumnus-registered studies. Physician manages all enrollment and eligibility determination.

Channel specifications

Channel parameters.

Enrolled slots

Available across registered studies

Sponsor payment

Flat-fee — per agreement

Screen failure

Low — credentialed network

Panel input

Any structured genomic result

Indications

Prostate · Bladder · RCC

Bioregulator studies

27 registered — enrollment open

Eligibility output

Field-by-field per criterion

Data sharing

None required from sponsor

Bioregulator study registry

Registered observational studies. Enrollment open.

Atumnus LLC. ClinicalTrials.gov. FDAAA 801. IRB-approved protocols. BPC-157, MOTS-c, Epithalon, Semax, KPV, and 22 additional compounds. No current ClinicalTrials.gov matching platform indexes this compound category. Companion diagnostic testing channel available to sponsors outside Medicare billing.

BPC-157

4 studies

Musculoskeletal, gut mucosa

MOTS-c

3 studies

Metabolic function, mitochondrial

Epithalon

4 studies

Telomere biology, circadian

Semax

3 studies

Neuroprotection, cognitive

KPV

3 studies

Inflammation, mucosal repair

Additional compounds

10 studies

See registry

Sponsor inquiry

Companion diagnostic testing inquiry

Inquiries reviewed within 5 business days. Include the indication, phase, and approximate enrollment target. Existing panel relationships do not affect eligibility for the channel.